Workshop on Future Opportunities for
Combination Biological Therapy of Cancer

Workshop Main Page   |   Presentations Slides & Schedules   |   Published Documents & News Releases
CME Information   |   Faculty

November 1, 2007
Seaport World Trade Center
Boston, Massachusetts

Workshop Offers 7.0 CME Credits

The Workshop has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of the Clinical Immunology Society and the International Society for Biological Therapy of Cancer. The Clinical Immunology Society is accredited by the ACCME to provide continuing medical education for physicians.

The Clinical Immunology Society designates this educational activity for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should claim credit commensurate with the extent of their participation in the activity.

Intended Audiences

The target audience for the Workshop incorporates basic and clinical investigators from academic, regulatory, and biopharmaceutical venues. The audience includes clinicians, researchers, students, post-doctoral fellows, and allied health professionals.

Program Objectives

1. Promote scientific dialogue regarding the most recent advances utilizing biologic agents in combination for the treatment of cancer
2. Facilitate collaboration between laboratory and clinical investigators
3. Facilitate interactions among scientists in academia, industry, and regulatory agencies regarding opportunities for the development of combination approaches for the biological therapy of cancer
4. Discuss regulatory issues that impact clinical trials using biologic agents in combination
5. Educate students, post-doctoral fellows, and junior faculty regarding issues in the development of new treatment approaches using biologic agents in combination
6. Offer opportunities for trainees to interact with senior investigators and leaders in the field

Expected Outcomes

1. Attendees will be familiarized with the latest issues regarding the development of therapeutic strategies using biologic agents in combination with other antineoplastic agents
2. Productive collaborative interactions between laboratory and clinical investigators will be established
3. Communication and collaboration will be enhanced among investigators from academia, industry, and regulatory agencies leading ultimately to improvements in the development of combination therapies
4. Investigators will gain an improved awareness of the regulatory and legal aspects of developing clinical trials using biologic agents in therapeutic combinations

Claiming CME

Email correspondence will be sent to all attendees at the conclusion of this program with specific instructions to claim a CME certificate.

Click here to claim your CME credits.